Objective: To investigate the clinical effect and safety of electroencephalographic biofeedback therapy in improving memory disorders in patientsin the recovery stage of acute severe toxic encephalopathy. Methods: A total of 52 patients in the recovery stage of acute severe toxic encephalopathy who were hospitalized in our hospital from March 2013 to December 2016 were enrolled and randomly divided into observation group with 27 patients and control group with 25 patients. Both groups were given the drugs to promote the metabolism of brain cells,and the patients in the observation group were given electroencephalographic biofeedback therapy in addition. The Chinese revised version of Wechsler Memory Scale Type A was used to measure memory ability before and after each course of treatment. The treatment outcome was evaluated for both groups. Results: There were no significant differences in the scores of long-term memory,short-term memory, immediate memory, and memory quotient between the two groups before treatment(P>0.05).After the first course of treatment ended, the observation group had significant increases in the scores of forward task,backward task,association,and memory quotient(P<0.05); compared with the control group, the observation group had a significant reduction in the score of backward task(P<0.05).After the second course of treatmentended, the observation group had significant increases in the scores offorward task,backward task,memorization of pictures,reproduction,association,comprehension,and memory quotient,and the control group had significant increases in the scores of reproduction,association,comprehension,and memory quotient(P<0.05); compared with the control group, the observation group had significant increases in the scores of forward task,backward task,memorization of pictures, reproduction, association, comprehension, and memory quotient(P<0.05).Two patients experiencedchest distress, palpitation, and dysphoria during treatment, which did not affect the treatment. Conclusion Electroencephalographic biofeedback therapy has a certain effect in the treatment of memory disorders in patients with acute severe toxic encephalopathy.

Objective Cariprazine is the first orally active dopamine D3-preferring D3/D2 receptor partial agonist as antipsychotic agents.It receives a lot of concern for its remarkable efficacy and broad market prospect.In this article,overall application status of cariprazine patent,which includes the patent application quantity,applicants and technical topics,as well as possible technical obstacles were statistically analyzed.Methods The patent quantitative analysis method was used,combing with pharmacy expertise,to analyze the patent application situation at home and abroad.Results The patent technology of cariprazine involves product,process,new use,component of combination,formulation and general interest.Conclusions The concern of patent situation for cariprazine was high.Patents about different salt and its crystal,analytical method and impurities should be dug up by domestic generic pharmaceutical enterprises for further generic drug development considering the existing technology barrier.